Screener
Kiniksa Pharmaceuticals International, plc KNSA Accounts Payable
Accounts Payable at other companies
Other financials
Where this comes from
Reported directly by Kiniksa Pharmaceuticals International, plc in its filing.
Tagged under the XBRL concept us-gaap:AccountsPayableCurrent.
The source filing: Kiniksa Pharmaceuticals International, plc’s 10-Q, filed July 28, 2026.
- Filed
- Jul 28, 2026, 4:17 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001104659-26-087545
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Total assets | $896,110 | $763,633 |
| Liabilities and Shareholders’ Equity | ||
| Current liabilities: | ||
| Accounts payable | $12,404 | $2,028 |
| Accrued collaboration expenses | 88,049 | 70,015 |
| Accrued expenses | 46,730 | 42,020 |
| Operating lease liabilities | 4,012 | 2,987 |
| Other current liabilities | 20,052 | 22,134 |
Item 1. Financial Statements (unaudited)
FAQ
- What is Kiniksa Pharmaceuticals International, plc's accounts payable?
- Kiniksa Pharmaceuticals International, plc (KNSA) reported accounts payable of $12.4M in Q2 2026.
- How has Kiniksa Pharmaceuticals International, plc's accounts payable changed year-over-year?
- Kiniksa Pharmaceuticals International, plc's accounts payable increased by 38.5% year-over-year, from $8.96M to $12.4M.
- What is the long-term trend for Kiniksa Pharmaceuticals International, plc's accounts payable?
- Over 5 years (2020 to 2025), Kiniksa Pharmaceuticals International, plc's accounts payable has grown at a 32.2% compound annual growth rate (CAGR), from $503K to $2.03M.
- What does accounts payable mean?
- Amounts owed to suppliers and vendors for goods and services received but not yet paid. A primary source of short-term trade financing.
Ask your AI about Kiniksa Pharmaceuticals International, plc's accounts payable.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude